Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|12|1714-1721

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.12, 2015-12, pp. : 1714-1721

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1202-1211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1202-1211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 896-901

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite